India vs. US:

Trade Tensions Heat UpIndia is ready to hit back with $1.91 billion in tariffs on key US goods—like almonds, petrochemicals, and medical devices—if steel and aluminium duties aren’t withdrawn by June 8. The trigger? Trump’s extension of safeguard duties. Commerce Minister Piyush Goyal heads to Washington on May 16 to try and broker a deal. With $7.6B in exports on the line and a 90-day tariff pause set to expire on July 8, India’s playing hardball while still betting on a Free Trade Agreement.

Airtel’s Q4 Rings Loud

Bharti Airtel posted a stunning 432% jump in Q4FY25 net profit at ₹11,022 crore, riding high on tariff hikes and a one-time tax gain. Revenue rose 27% to ₹47,876 crore, while ARPU hit ₹245. With 590.5 million users, the company also sealed a satellite internet pact with Elon Musk’s Starlink. A ₹16/share final dividend caps off a blockbuster year.

Tata’s Mixed Drive

Tata Motors saw Q4 profit drop 51% YoY to ₹8,470 crore, but FY25 revenue hit a record ₹4.39 lakh crore. JLR’s PBT soared to a decade-high £2.5 billion, and Tata’s EV arm turned EBITDA positive. Challenges persist in passenger vehicles, but the company remains debt-free and optimistic. A ₹6 dividend and a key Investor Day on June 16 are on the radar.

Hero’s Global EV Push

Hero MotoCorp’s FY25 net profit rose 16% to ₹4,610 crore. Exports jumped 44%, and EV sales rocketed 175%, with its Vida brand doubling market share. But rivals like Honda and TVS are growing faster. Hero plans European expansion and is betting big on EVs and new three-wheeler plays via Euler Motors.

Cipla Steady Amid Policy Storm

Cipla shrugged off US pharma tariff fears and posted a 30% jump in Q4 profit to ₹1,222 crore. FY25 revenue grew 8% to ₹27,548 crore. The US remains key, now forming 29% of revenue, while India remains the long-term play. With GLP-1 drugs like Ozempic going off patent soon, Cipla’s gearing up with in-house and partner products for the next leg of growth.